Sirtex Sweats as Share Price Drops

What happened to the Sirtex Share Price?

Sirtex Medical Ltd. [ASX:SRX] share price has slumped by 28.40% in intra-day trading as of 2:47pm.
Yesterday Sirtex requested to halt trading so they could analyse new research results. Those results came in today. Findings were less than stellar, sending the share price tumbling.

Why did this happen to the SRX Shares?

The company has been testing SIR-spheres to treat liver cancer in conjunction with chemotherapy. The spheres are designed to surround and destroy tumour cells while minimising damage to healthy liver tissue.

The results from the study found that Sirtex’s SIR-sphere technology wasn’t effective enough at lowering death rates in patients. CEO Nigel Lange was disappointed with the results. But he noted a 36% reduction in risk of death for right-sided colon cancer was a small positive.

What now for Sirtex Medical Shares?

Lange expected a minimal impact on trade. He highlighted that most patients Sirtex trialled had failed standard chemotherapy treatments. Shareholders clearly didn’t see it that way.

On the back of this poor results data Sirtex took another blow. Chief executive of the US branch, Kevin Richardson confirmed to have quit.


Ryan Clarkson-Ledward
For Money Morning

At Money Morning our aim is simple: to give you intelligent and enjoyable commentary on the most important stock market news and financial information of the day - and tell you how to profit from it. We know the best investments are often the hardest to find. So that's why we sift through mountains of reporting, research and data on your behalf, to present you with only the worthwhile opportunities to invest in.

Become a more informed, enlightened and profitable investor today - by taking out your free subscription to Money Morning now.

Money Morning Australia